Q1 Earnings Forecast for CorMedix Issued By Leerink Partnrs

CorMedix Inc. (NASDAQ:CRMD) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for CorMedix in a research report issued to clients and investors on Tuesday, March 25th. Leerink Partnrs analyst R. Ruiz expects that the company will earn $0.23 per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for CorMedix’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.16 EPS, Q4 2025 earnings at $0.29 EPS, FY2025 earnings at $0.73 EPS, FY2026 earnings at $2.50 EPS, FY2027 earnings at $3.20 EPS and FY2028 earnings at $3.65 EPS.

CorMedix (NASDAQ:CRMD) last released its earnings results on Tuesday, March 25th. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.05. The company had revenue of $30.00 million for the quarter, compared to the consensus estimate of $27.46 million. The company’s revenue was up 29900.0% compared to the same quarter last year.

A number of other equities analysts also recently weighed in on the stock. D. Boral Capital restated a “buy” rating and set a $15.00 target price on shares of CorMedix in a report on Tuesday, March 25th. Needham & Company LLC reduced their target price on shares of CorMedix from $18.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and issued a $12.00 price target on shares of CorMedix in a research note on Wednesday. Finally, Leerink Partners assumed coverage on shares of CorMedix in a research note on Friday, March 7th. They set an “outperform” rating and a $18.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.14.

CorMedix Stock Up 0.4 %

Shares of CorMedix stock opened at $6.74 on Friday. The stock has a market cap of $408.96 million, a P/E ratio of -8.32 and a beta of 1.53. CorMedix has a 12-month low of $3.61 and a 12-month high of $13.85. The business’s 50 day moving average is $10.43 and its 200-day moving average is $9.91.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. FMR LLC boosted its stake in shares of CorMedix by 54.3% in the 3rd quarter. FMR LLC now owns 4,618 shares of the company’s stock valued at $37,000 after purchasing an additional 1,625 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in CorMedix during the 4th quarter worth approximately $81,000. Captrust Financial Advisors bought a new position in CorMedix in the 4th quarter valued at approximately $90,000. Aigen Investment Management LP acquired a new stake in CorMedix in the fourth quarter valued at approximately $94,000. Finally, XTX Topco Ltd bought a new stake in shares of CorMedix during the fourth quarter worth $95,000. Institutional investors and hedge funds own 34.18% of the company’s stock.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.